The document provides examples of diagrams and figures before and after being redrawn by Charles Kent Ltd, a visual communications specialist, for use in posters, presentations, and manuscripts, showing their work in restructuring and standardizing complex scientific diagrams to be more clear and reader-friendly. It also includes examples of their work redrawing graphs and charts from published studies to improve visual presentation. The document demonstrates Charles Kent Ltd's expertise in figure layout and redrawing for optimized communication of scientific concepts, data, and study results.

1. Charles Kent Ltd
ePortfolio

2. Charles Kent Ltd
Visual Communications Specialist

3. Diagrams

4. Before…

5. …After
ANP
Hypertrophic gene program
Ca2+
Ca2+
Calcineurin
NFAT
NFATGATA
CaMKII
PKG
RGS2
Angiotensin II
TRPC 3/6 GPCR
GC-A
TRRC
MCP
IP3
NFAT
P
P
PLC
RGS2
Goq
GTP

6. Before…
Pre-launch Launch Post-Launch
Online resource
for oncologists
and pathologists
a therapy area
portal approach
Brand website
New MOAfor
EGFR-TKI
Plugging into the
established
communication networks
Congress activities
EGFRtesting
app
Augmented reality/
interactive sales aids
Patient portal
Materials
produced in
conjunction
with patient
organisations
Multichannel integration:Our approach is to ensure activities are integrated into the communication strategy to
enable maximum reach with key stakeholders with consistent messaging across all channels
Booth materials

7. After…
PRE-LAUNCH LAUNCH POST-LAUNCH
Congress activities
Plugging into the
established
communication networks
Patient portal
Online resource for
oncologists and
pathologists a
therapy area
portal approach
New MOA for
EGFR-TKI
Materials
produced in
conjunction
with patient
organisationsBooth materials
Augmented reality/
interactive sales aids
Brand website
EGFR
testing app
> Multichannel integration: Our approach is to ensure activities are integrated into the communication
strategy to enable maximum reach with key stakeholders with consistent messaging across all channels

8. Before…
Induction +28–42d post
cycle 4,
Maintenance 25m post
cycle 4
Product A
375 mg/m2 IV
Product A
375 mg/m2 IV
• Relapsed CD20+
iNHL
• Prior response
>6 mo to last
Product A rx
ABC101
( Product B )
1000 mg IV
ABC101
( Product B )
1000 mg IV
9
PD Discontinue
Treatment
CT/PET

CT/PET

CT CT CT
CT
   
3m 6m 12m
18m
CT

25m
Randomized phase II trial comparing ABC101 (Product B) with product A in patients
with relapsed CD20+ indolent B-cell NHL
w1 w2 w3 w4 m2 m4 m6 m24
………
RANDOMIZATION
EndofInduction
EndofMaintenance

9. After…
• Relapsed CD20+
iNHL
• Prior response
6 mo to last
product A rx
Induction Maintenance
Product A
375 mg/m2 IV
Product A
375 mg/m2 IV
ABC101
(Product B)
1000 mg IV
ABC101
(Product B)
1000 mg IV
End of
induction
End of
maintenance
+28–42d
post cycle 4
25m post
cycle 4
CT/PET
Randomization
CT CT CT CT CTCT/PET
3m 6m 12m 18m 25m
PD discontinue treatment
Randomized phase II trial comparing ABC101 (Product B) with product A
in patients with relapsed CD20+ indolent B-cell NHL
w1 w2 w3 w4 m2 m4 m6 m24

10. Before…

11. After…
Standardised measures to
track/quantify symptoms
(eg ACT, ASQ, CAT)
Peak flow diary results,
spirometry results/pulmonary
function tests (FEV1)
If patient presents to HCP (outside of a
routine consultation) this is first indicator
that they may not be ‘controlled’
Basic questions about symptoms
experienced and exposure to triggers
(many have a battery of questions they use)
Symptom
quantification
Objective
clinical
measures
Symptom report /
questioning
Patient presentation
ACT and ASQ are useful but we
don’t go through each of them,
just pick specific questions.
SPECIALIST, Dublin
Ultimately it is a clinical syndrome
so we are looking at that rather
than lab measures to monitor.
SPECIALIST, Dublin
If they are not
seeing us we hope
they are controlled.
NURSE, Manchester
Less
used

12. Layout

17. Figure Redrawing for Posters,
Presentations & Manuscripts

18. Before…

19. After…LVEDV(ml)
0
100
200
300
LVESV(ml)
0
100
200
SV(ml)
0
40
60
80
20
*
EF(%)
0
20
40
60
TPR
(dyne-sec-cm–5)
0
2000
3000
ANF(pg/ml)
0
40
60
20
* *
* *
**
* *
* *
*
**
1000
* *
Controls CHF Controls CHF
Base 60’ 120’ Base 60’ 120’ Base 60’ 120’ Base 60’ 120’
Time (minutes) Time (minutes)
**
* *
* *
**
* *
**
*
*
*
*

20. Before…
Comparator 1 – Overall Survival
Prior Platinum Exposure
HR 1.23 (95% CI 0.45-6.78)
RR: 12% (CP) vs 34% (TP)
HR 1.23 (95% CI 0.45-6.78)
RR: 12% (CP) vs 34% (TP)
Prior Comparator A No Prior Comparator A
Comparator A backbone
Comparator A backbone
Comparator B backbone
Comparator B backbone

21. After…
Comparator 1 – Overall Survival
Prior Platinum Exposure`
Proportionsurviving
Months on Study
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 2412 186
Prior Comparator A No Prior Comparator A
Proportionsurviving
Months on Study
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 2412 186
HR: 1.23 (95% CI 0.45–6.78)
RR: 12% (CP) vs 34% (TP)
HR: 1.23 (95% CI 0.45–6.78)
RR: 12% (CP) vs 34% (TP)
Comparator
A
Comparator
B
Alive 123 45
Dead 67 89
Total 112 345
Comparator
A
Comparator
B
Alive 123 45
Dead 67 89
Total 112 345

22. Before…

23. After…SV(ml)
0
50
100
ANF(pg/ml)
0
60
20
180 280 180 280
Untreated CEI
Base
60’
120’
Volume Expansion

24. Before…

25. After…

26. Software Applications

27. Advanced User:
Adobe Illustrator CC
Adobe Photoshop CC
Adobe InDesign CC
Adobe Acrobat
Microsoft Powerpoint (2013)
Microsoft Word (2013)
Microsoft Excel (2013)
Quark Express